Literature DB >> 22740338

Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Erin Kim1, Joan Cook-Mills, Gabrielle Morgan, Simone T Sredni, Lauren M Pachman.   

Abstract

OBJECTIVE: To evaluate the effect of duration of untreated disease on vascular cell adhesion molecule 1 (VCAM-1) and microRNA (miRNA) expression in muscle biopsy samples from children with juvenile dermatomyositis (DM) as well as its effect on soluble VCAM-1 (sVCAM-1) and tumor necrosis factor α (TNFα) concentrations in sera from these children.
METHODS: We enrolled 28 untreated children with juvenile DM and 8 pediatric controls. Eleven children with juvenile DM had short duration of untreated disease (symptoms for ≤2 months before muscle biopsy), and 17 had long duration of untreated disease (symptoms for >2 months before muscle biopsy). Vascular structures, characterized by immunofluorescence using antibodies against von Willebrand factor, VCAM-1, and α-smooth muscle actin, were measured for total area and intensity. Circulating sVCAM-1 and TNFα levels were determined in patients with short duration of untreated disease, patients with long duration of untreated disease, and controls. Differential expression of microRNA-126 (miR-126) in muscle biopsy samples from the 2 patient groups and the control group was detected by miRNA expression profiling and confirmed by quantitative reverse transcription-polymerase chain reaction in muscle biopsy samples from the 3 groups.
RESULTS: Juvenile DM patients with short duration of untreated disease had significantly higher total positive area and intensity/high power field of VCAM-1 expression than did juvenile DM patients with long duration of untreated disease (P = 0.043 and P = 0.015, respectively) or controls (P = 0.004 and P = 0.001, respectively). Von Willebrand factor antigen-positive vasculature displayed greater VCAM-1 intensity in patients with short duration of untreated disease than in patients with long duration of untreated disease (P = 0.001). Circulating levels of sVCAM-1 and TNFα were significantly higher in patients with short duration of untreated disease than in controls (P = 0.013 and P = 0.048, respectively). The miRNA miR-126, a negative regulator of VCAM-1 expression, was significantly decreased (3.39-fold; P < 0.006) in patients with short duration of untreated disease compared to controls, while miR-126 expression in patients with long duration of untreated disease did not differ significantly compared to controls.
CONCLUSION: In patients with short duration of untreated disease, miR-126 down-regulation is associated with increased VCAM-1 in both muscle and blood, suggesting that VCAM-1 plays a critical role early in juvenile DM disease pathophysiology, augmented by TNFα.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740338      PMCID: PMC3469762          DOI: 10.1002/art.34606

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

1.  Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.

Authors:  K Yamane; H Ihn; M Kubo; N Yazawa; K Kikuchi; Y Soma; K Tamaki
Journal:  J Am Acad Dermatol       Date:  2000-01       Impact factor: 11.527

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

3.  Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.

Authors:  Rachel Lynne Smith; Joyce Sundberg; Eli Shamiyah; Alan Dyer; Lauren M Pachman
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

4.  Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM).

Authors:  M C Cid; J M Grau; J Casademont; E Tobías; A Picazo; B Coll-Vinent; J Esparza; E Pedrol; A Urbano-Márquez
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

5.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 6.  Adhesion molecules in autoimmune disease.

Authors:  R W McMurray
Journal:  Semin Arthritis Rheum       Date:  1996-02       Impact factor: 5.532

7.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Aneel Gursahaney; Ka-Leung Ngai; Jennifer A Daru; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02-15

8.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Authors:  Stéphanie Christen-Zaech; Roopa Seshadri; Joyce Sundberg; Amy S Paller; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02

Review 9.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis.

Authors:  Carmen Urbich; Angelika Kuehbacher; Stefanie Dimmeler
Journal:  Cardiovasc Res       Date:  2008-06-11       Impact factor: 10.787

10.  The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes.

Authors:  Hyun Su Ryu; Seung-Yoon Park; Duan Ma; Jin Zhang; Wan Lee
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more
  14 in total

Review 1.  Epigenetics in Non-tumor Immune-Mediated Skin Diseases.

Authors:  M C Ovejero-Benito; E Daudén; Alejandra Reolid; E Muñoz-Aceituno; F Abad-Santos
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

Review 2.  Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.

Authors:  Kirsty McLellan; Charalampia Papadopoulou
Journal:  Curr Rheumatol Rep       Date:  2022-06-10       Impact factor: 4.686

Review 3.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 4.  The role of microRNAs in skeletal muscle health and disease.

Authors:  Tyler J Kirby; Thomas Chaillou; John J McCarthy
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

5.  Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis.

Authors:  Qing-Lin Peng; Ya-Mei Zhang; Han-Bo Yang; Xiao-Ming Shu; Xin Lu; Guo-Chun Wang
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

Review 6.  Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases.

Authors:  Simona Ultimo; Giorgio Zauli; Alberto M Martelli; Marco Vitale; James A McCubrey; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2018-03-30

Review 7.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Authors:  Judith Wienke; Claire T Deakin; Lucy R Wedderburn; Femke van Wijk; Annet van Royen-Kerkhof
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

Review 8.  MicroRNAs in skeletal muscle and their regulation with exercise, ageing, and disease.

Authors:  Evelyn Zacharewicz; Séverine Lamon; Aaron P Russell
Journal:  Front Physiol       Date:  2013-09-30       Impact factor: 4.566

Review 9.  Update in juvenile myositis.

Authors:  Kiran Nistala; Lucy R Wedderburn
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

Review 10.  Involvement of miR-126 in autoimmune disorders.

Authors:  Marco Casciaro; Eleonora Di Salvo; Teresa Brizzi; Carmelo Rodolico; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2018-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.